Trials / Not Yet Recruiting
Not Yet RecruitingNCT06447454
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
Chemoradiotherapy Combined With Slulimumab in the Treatment of First-line Intrahepatic Cholangiocarcinoma: Efficacy and Safety Evaluation of a Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 19 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | radiotherapy | radiotherapy |
| DRUG | gemcitabine + cisplatin | Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks. |
| DRUG | slulimumab | Slulimumab, 4.5mg/kg intravenous infusion, Q3W |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
- First posted
- 2024-06-07
- Last updated
- 2024-06-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06447454. Inclusion in this directory is not an endorsement.